Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios Dimopoulos

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|November 29, 2008
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jawBeatrice J Edwards, Mrinal Gounder, June M McKoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancerNicoletta Colombo, Elzbieta Kutarska, Meletios Dimopoulos, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2020
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With LenalidomideBarbara Gamberi, Christian Berthou, Miguel Hernandez, et al.
Hemasphere|November 15, 2019
Is Good Clinical Practice Becoming Poor Clinical Care?Steven Le Gouill, Martin Dreyling, Maria Dolores Caballero, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Clinical Lymphoma & Myeloma|April 28, 2006
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's MacroglobulinemiaEva Kimby, Steven P Treon, Athanasios Anagnostopoulos, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|November 29, 2008
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jawBeatrice J Edwards, Mrinal Gounder, June M McKoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancerNicoletta Colombo, Elzbieta Kutarska, Meletios Dimopoulos, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2020
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With LenalidomideBarbara Gamberi, Christian Berthou, Miguel Hernandez, et al.
Hemasphere|November 15, 2019
Is Good Clinical Practice Becoming Poor Clinical Care?Steven Le Gouill, Martin Dreyling, Maria Dolores Caballero, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Clinical Lymphoma & Myeloma|April 28, 2006
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's MacroglobulinemiaEva Kimby, Steven P Treon, Athanasios Anagnostopoulos, et al.
Pageof 12